administration vorinostat disrupts hiv- latency patients antiretroviral therapy 
despite antiretroviral therapy proviral latency human immunodeficiency virus type hiv- remains principal obstacle curing infection1 inducing expression latent genomes within resting cd4+ t cells primary strategy clear reservoir23 although histone deacetylase inhibitors suberoylanilide hydroxamic acid also known vorinostat vor can disrupt hiv- latency vitro4- utility approach never directly proven translational clinical study hiv-infected patients isolated circulating resting cd4+ t cells patients viraemia fully suppressed antiretroviral therapy directly studied effect vor latent reservoir eight patients single dose vor increased biomarkers cellular acetylation simultaneously induced increase hiv rna expression resting cd4+ cells mean increase -fold demonstrates molecular mechanism known enforce hiv latency can therapeutically targeted humans provides proof-of-concept histone deacetylase inhibitors therapeutic class defines precise approach test novel strategies attack eradicate latent hiv infection directly 
